How to Value a Fertility Clinic in 2026

Fertility clinics are among the most valuable medical practices in the country, and the M&A activity in reproductive endocrinology has been relentless. PE-backed platforms like Kindbody, Prelude Fertility, and CCRM have been acquiring clinics at aggressive multiples, and the fundamentals support it: delayed parenthood trends, expanding insurance mandates, and a severe shortage of board-certified reproductive endocrinologists. I've advised on fertility transactions ranging from single-physician practices to multi-location platforms, and the valuation dynamics here are unlike any other medical specialty.

The Multiples: 8-15x EBITDA

Fertility clinics trade at 8-15x EBITDA, among the highest multiples in all of healthcare M&A. The range is wide because the variables that separate an 8x practice from a 15x platform are enormous. A solo REI physician with 200 cycles per year and aging lab equipment is a fundamentally different asset than a three-location practice with 1,500+ annual cycles, a state-of-the-art embryology lab, and published SART data showing above-average success rates.

EBITDA is the universal metric here because fertility clinics generate enough revenue and margin to attract institutional buyers. Most practices worth selling are doing $3M-$20M+ in revenue with 25-40% EBITDA margins. At these levels, PE firms and platform acquirers are your buyer pool, and they think in EBITDA multiples.

Cycle Count Is Your Core Metric

Every fertility clinic valuation starts with cycle volume. Annual IVF cycle count is to fertility what collections are to dentistry — the single number that anchors everything else. Buyers want to see how many fresh and frozen embryo transfer cycles you perform per year, and they want to see that number growing.

The economics are straightforward. A single IVF cycle generates $12,000-$20,000 in revenue (before medications, which may or may not flow through your practice). A clinic performing 500 cycles per year is generating $6M-$10M in cycle revenue alone, plus ancillary income from monitoring, genetic testing, egg freezing, donor programs, and fertility preservation.

What buyers scrutinize is cycle growth trajectory. A clinic that grew from 300 to 500 cycles over three years demonstrates market demand and operational capacity. A clinic that's been flat at 400 cycles for five years raises questions: is the market saturated, is the physician at capacity, or is something else constraining growth?

Live Birth Rate: The Outcome That Matters

Fertility is one of the only medical specialties where outcomes data is publicly reported. The Society for Assisted Reproductive Technology (SART) publishes clinic-level success rates, and every sophisticated buyer will pull your SART data before making an offer. Your live birth rate per transfer is, in many ways, your brand.

Clinics with above-average SART outcomes command premium multiples for two reasons. First, outcomes drive referrals — OB/GYNs and patients research success rates before choosing a clinic. Second, outcomes correlate with embryology lab quality, physician skill, and protocol sophistication — all things that transfer to a new owner.

Conversely, below-average outcomes create real valuation risk. A buyer will question whether the lab needs upgrading, whether protocols are outdated, or whether the physician is underperforming. I've seen clinics with strong financials take 1-2x EBITDA haircuts because their published success rates lagged the national average.

The Embryology Lab: Your Most Valuable Asset

The embryology lab is the heart of a fertility practice, and its quality has an outsized impact on valuation. A modern, well-equipped lab with redundant systems and experienced embryologists is worth far more than its book value in equipment. Buyers are really valuing the lab's capability and track record.

Lab equipment alone represents a significant capital investment — typically $1M-$3Mfor a fully equipped IVF lab including incubators, micromanipulation systems, cryopreservation tanks, clean room infrastructure, and environmental monitoring. But the equipment is the easy part to replicate. What's harder to replicate is a lab team with a proven track record.

Experienced embryologists are extraordinarily scarce. There are roughly 1,200 board-certified embryologists in the United States serving 500+ clinics. A senior embryologist with a consistent fertilization rate above 80% and blastocyst development rate above 55% is worth their weight in gold — and their retention post-acquisition is a major negotiation point. I always advise sellers to have employment agreements or retention bonuses in place for key lab staff before going to market.

Cash-Pay Dynamics and Revenue Quality

Fertility is one of the most cash-pay-heavy specialties in medicine, and this has profound implications for valuation. In states without fertility insurance mandates, 60-80% of IVF revenue comes directly from patients. Even in mandate states like Massachusetts, Connecticut, and Illinois, significant portions of treatment fall outside covered benefits.

Buyers view heavy cash-pay revenue as a double-edged sword. On one hand, you avoid insurance reimbursement risk, prior authorization hassles, and payer concentration. Cash-pay patients pay at the time of service, so collections are near-immediate and write-offs are minimal. That's enormously attractive from a revenue quality perspective.

On the other hand, cash-pay demand is sensitive to economic conditions and consumer confidence. During the 2008-2009 recession, many fertility clinics saw cycle volumes drop 15-25%. Buyers factor this cyclicality into their models. The mitigating factor is the secular trend: average maternal age continues to rise, fertility benefits are expanding as an employer perk, and egg freezing has become mainstream. These tailwinds have outweighed economic sensitivity in recent years.

The REI Physician Shortage and Its Impact

There are approximately 1,400 board-certified reproductive endocrinologists in the United States. The fellowship training pipeline produces about 50 new REIs per year, while demand for fertility services grows 5-8% annually. This supply-demand imbalance is the fundamental reason fertility practice multiples are so high — and it creates both opportunity and risk in a transaction.

The opportunity: every REI physician represents a scarce, revenue-generating asset that a platform desperately needs. When a PE firm acquires your clinic, they're buying access to a physician they couldn't recruit otherwise.

The risk: if you're a solo REI practice, the buyer knows you ARE the practice. Your post-acquisition employment agreement — typically 3-5 years with restrictive covenants — becomes the most important document in the deal. I've seen fertility transactions where 30-40% of the purchase price was structured as retention payments and earn-outs tied to the physician staying and maintaining cycle volume.

What Drives Premium Valuations

The fertility clinics I've seen trade at 12-15x EBITDA share several characteristics:

• Multiple REI physicians: Reduces key-person risk and demonstrates the practice can function beyond any single provider. Two or more REIs is the threshold most platforms want.
• Growing cycle volume: 10%+ annual cycle growth signals market demand and operational capacity to scale.
• Diversified revenue streams: IVF cycles plus egg freezing, donor programs, genetic testing, and fertility preservation. Platform buyers want to see ancillary revenue comprising 20-30% of total.
• Geographic positioning: Practices in underserved markets or states with new fertility mandates command premiums because platforms need geographic coverage.
• Above-average SART outcomes: Published success rates that consistently exceed national averages.

What Kills Fertility Practice Value

Solo physician with no succession plan. If you're the only REI and you haven't brought on a junior partner or associate, buyers see a practice that could collapse if you get injured, burn out, or decide to retire early. The earn-out will be aggressive and the upfront multiple will be discounted.

Aging lab infrastructure. Incubators, micromanipulation equipment, and cryogenic systems have finite lifespans. If a buyer walks into your lab and sees equipment that's 10-15 years old, they're mentally budgeting $1M-$2M in capital expenditures and deducting it from their offer.

Below-average outcomes. SART data is public. If your success rates lag your peers, no amount of financial engineering will close the gap. Buyers know that outcomes drive referrals, and referrals drive cycle volume.

Regulatory exposure. Fertility is heavily regulated — CLIA, state laboratory licenses, FDA tissue banking regulations, and evolving state laws around embryo disposition. Any compliance gaps discovered during due diligence will either kill the deal or result in significant escrow holdbacks.

The Bottom Line

Fertility clinic valuation is driven by physician scarcity, lab capability, and published outcomes in a way that no other medical specialty can match. The 8-15x EBITDA range reflects genuine variance in practice quality, and the difference between a good deal and a great one often comes down to preparation: recruiting a second physician, investing in lab upgrades, and building the ancillary revenue streams that platforms value. If you're an REI physician thinking about your exit, start planning at least 3 years out — the moves that maximize your multiple take time to execute.